Q3 Earnings Forecast for GH Research Issued By HC Wainwright

Key Points

• HC Wainwright has increased its Q3 2025 earnings per share estimate for GH Research from ($0.22) to ($0.19), maintaining a "Buy" rating with a price target of $40.00.
• The current consensus estimate for GH Research's full-year earnings is ($0.80) per share, while the stock has experienced a recent increase of 3.5%.
• Institutional investors now own 56.90% of GH Research's stock, with notable increases in positions from multiple hedge funds in the recent quarters.

GH Research PLC (NASDAQ:GHRS - Free Report) - Analysts at HC Wainwright upped their Q3 2025 earnings per share (EPS) estimates for shares of GH Research in a research report issued to clients and investors on Monday, August 11th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings per share of ($0.19) for the quarter, up from their previous forecast of ($0.22). HC Wainwright currently has a "Buy" rating and a $40.00 price target on the stock. The consensus estimate for GH Research's current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for GH Research's Q4 2025 earnings at ($0.22) EPS, FY2025 earnings at ($0.74) EPS, Q1 2026 earnings at ($0.21) EPS, Q2 2026 earnings at ($0.19) EPS, Q3 2026 earnings at ($0.19) EPS, Q4 2026 earnings at ($0.19) EPS, FY2026 earnings at ($0.79) EPS, FY2027 earnings at ($0.84) EPS and FY2028 earnings at ($0.39) EPS.

GHRS has been the subject of a number of other reports. Wall Street Zen raised GH Research from a "sell" rating to a "hold" rating in a report on Saturday, July 5th. Zacks Research downgraded GH Research from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, August 13th. JMP Securities restated a "market outperform" rating and set a $39.00 price target on shares of GH Research in a report on Tuesday, June 24th. Guggenheim decreased their target price on GH Research from $32.00 to $29.00 and set a "buy" rating for the company in a research report on Friday, May 9th. Finally, Cantor Fitzgerald initiated coverage on GH Research in a research note on Wednesday, June 4th. They set an "overweight" rating and a $25.00 target price on the stock. Seven research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $32.00.

GH Research Stock Performance

Shares of GHRS stock traded down $0.11 during mid-day trading on Thursday, hitting $12.56. The company's stock had a trading volume of 51,400 shares, compared to its average volume of 337,286. GH Research has a 52 week low of $6.00 and a 52 week high of $20.50. The company has a market cap of $653.50 million, a PE ratio of -17.03 and a beta of 0.98. The company's fifty day simple moving average is $13.89 and its 200-day simple moving average is $12.20.

GH Research (NASDAQ:GHRS - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.07.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Cormorant Asset Management LP raised its holdings in shares of GH Research by 238.8% in the first quarter. Cormorant Asset Management LP now owns 2,009,482 shares of the company's stock worth $22,165,000 after buying an additional 1,416,439 shares during the period. Jefferies Financial Group Inc. purchased a new stake in shares of GH Research during the 1st quarter worth $8,272,000. Lynx1 Capital Management LP boosted its stake in GH Research by 15.8% in the fourth quarter. Lynx1 Capital Management LP now owns 4,858,994 shares of the company's stock valued at $34,013,000 after acquiring an additional 663,100 shares in the last quarter. Alyeska Investment Group L.P. acquired a new stake in GH Research in the first quarter valued at approximately $5,018,000. Finally, RA Capital Management L.P. grew its stake in shares of GH Research by 3.9% during the first quarter. RA Capital Management L.P. now owns 6,944,648 shares of the company's stock worth $76,599,000 after acquiring an additional 257,959 shares during the last quarter. Institutional investors own 56.90% of the company's stock.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).